MAIA

Maia Biotechnology Inc. (MAIA) | Rumor.io

Maia Biotechnology

MAIA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,702

Bullish sentiment (50-day avg)92%

Price to earnings ratio-1.67

Market capitalization71.8M

Earnings per share-0.63

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-22.4M

Social

What share of all stock conversation is about MAIA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jun 4

MAIA Biotechnology, Inc. has reported strong enrollment and dosing momentum in its pivotal Phase 3 non-small cell lung cancer trial.
The company's CEO has acquired large amounts of stock in the open market, indicating a strong incentive to maximize shareholder value.
The stock has shown a lack of movement despite positive developments, suggesting potential selling pressure or a lack of conviction among investors.

Generated by AI

Sentiment

Of the messages about MAIA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +43.75	90% -10	85.78% -1.67
Bearish	0% 0	0% -43.75	10% new	14.22% +1.67

Bullish· Jan 29

MAIA Biotechnology's Phase 3 data is expected to be positive, which could lead to a significant increase in the stock price.
The company's THIO Phase 2 results were exceptional, and if Phase 3 results are similar, it could disrupt the entire cancer therapy industry and reward shareholders.
MAIA's momentum is building, with strong technical indicators, including a weekly close above the Keltner upper band and a bullish RSI reading, suggesting a potential explosive surge in the stock price.

Bearish· Jun 4

$MAIA's price drop from positive news may discourage long-term investing, but it also presents a buying opportunity.
The stock's recent price decline is a classic example of the "buy the anticipation, sell the news" phenomenon, where anticipation of positive news leads to overvaluation and subsequent sell-off.
$MAIA's significant price drop may be attributed to the market's perception that the company needs substantial funding to move forward, leading to a negative reaction from investors.

Generated by AI

Topics

Of the messages about MAIA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	85.71%	82.35%	58.25%
Technical Analysis	0%	14.29%	17.65%	23.77%
Analysts	0%	0%	0%	2.06%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.1%
Macro	0%	0%	0%	15.82%

Announcements· Dec 1

MAIA Biotechnology's CEO and board members purchased 182,445 shares in late November 2025, signaling strong confidence in their cancer drug development program.
CEO Vlad Vitoc bought 94,300 shares at an average price of $1.08, while directors Cristian Luput and Stan V. Smith purchased 88,145 shares at an average price of $1.06.
The purchases were made under the company's open market purchase plan, with the CEO and directors loading shares at an average price of $1.06-$1.08.

Technical Analysis· Jul 23

$MAIA has been consolidating in the mid-3s after reaching a high of $5.99 in early June, and is expected to break out to $5+ in coming sessions.
The stock's chart is showing strong support at $3.4-$3.55, with a break above $3.80 potentially leading to a climb back over $4 and a test of premarket highs.
$MAIA's daily and weekly charts are setting up for the next wave up, with key resistance areas at $4.00, $4.12, and $4.32.

Generated by AI

Community

Of the messages about MAIA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	92%	32.45%	31.14%
Newcomers	0%	8%	67.55%	68.86%

Regulars· Feb 4

MAIA Biotechnology has announced positive efficacy updates for its Phase 2 THIO-101 trial in advanced non-small cell lung cancer, with median overall survival reaching 16.9 months.
The trial's data strengthens MAIA's regulatory strategy, with the company potentially positioning itself for accelerated FDA approval depending on the final results.
MAIA's stock price has surged following the announcement, with some analysts predicting a potential run-up to $2.5 or even $3, driven by strong volume and the company's growth projections.

Newcomers· Jan 20

New users are focusing on the significant price increase of MAIA, with one user mentioning an uptick of 15% and another expressing interest in the stock reaching 100%+.
The newcomers are excited about MAIA's advancing cancer treatment program, specifically the ateganosine program, and the potential for early approval.
One user is highlighting the stock's recent update, which includes the potential for Phase 3 interim data and the company's plan to target the $50B+ non-small cell lung cancer (NSCLC) market.

Generated by AI

Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3 million NIH grant to MAIA to support third-line treatment evaluation CHICAGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that

14d agoYahoo Finance

Maia Biotechnology CEO Vlad Vitoc buys $100,010 in company stock

15d agoInvesting.com

Maia Biotechnology director buys $49,516 in company shares

15d agoInvesting.com

MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026

Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vivo models CHICAGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced its presentation of a poster featuring its second-generation telomere-targeting anticancer drug candidates at the recent XXVI International Round Table on Nucleoside

20d agoYahoo Finance

Maia Biotechnology director Guerrero buys $2,386 in common stock

1mo agoInvesting.com

Also Discussed

Investors talking about MAIA also mention

#	Name	Attention
1	MGAM - Mobile Global Esports Inc.	——
2	SaverOne 2014 Ltd. ADRSVRE	0%new
3	Magic Empire Global Ltd Class A Ordinary SharesMEGL	0%0
4	AMTD Digital Inc. ADRHKD	0%new
5	Intelligent Living Application Group Inc.ILAG	0%new
6	Candel Therapeutics, Inc.CADL	0.03%+0.02
7	Coeptis Therapeutics, Inc.COEP	0%new
8	Getty Images Holdings, Inc. Class A Common StockGETY	0.01%0
9	HERA - FTAC Hera Acquisition Corp.	——
10	NeuroOne Medical Technologies CorporationNMTC	0%0

Maia Biotechnology Inc.

Healthcare
Biotechnology

Maia Biotechnology Inc. is a biotechnology company primarily focused on developing and commercializing therapies to treat cancer. With an emphasis on innovative treatment approaches, the company is known for its proprietary program that targets significant oncology indications, underlining its commitment to transforming the current landscape of cancer treatment. Maia Biotechnology’s pipeline features novel therapies engineered to harness the body's immune system, aiming to offer new hope for patients where traditional treatments have proven ineffective. The biotech industry, particularly in oncology, is pivotal given the rising global cancer burden, and Maia Biotechnology is positioned at the forefront of these crucial medical advancements. By focusing on targeted therapies and addressing unmet needs in cancer care, Maia Biotechnology plays a significant role in both the healthcare sector and the broader efforts to improve patient outcomes in oncology. Through rigorous research and development, the company strives to bring innovative solutions that could potentially have a substantial impact on the quality of life for cancer patients worldwide.

Website

Location

444 West Lake Street

Chicago, IL, 60606

United States

Social

What share of all stock conversation is about MAIA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jun 4

MAIA Biotechnology, Inc. has reported strong enrollment and dosing momentum in its pivotal Phase 3 non-small cell lung cancer trial.
The company's CEO has acquired large amounts of stock in the open market, indicating a strong incentive to maximize shareholder value.
The stock has shown a lack of movement despite positive developments, suggesting potential selling pressure or a lack of conviction among investors.

Generated by AI

Sentiment

Of the messages about MAIA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +43.75	90% -10	85.78% -1.67
Bearish	0% 0	0% -43.75	10% new	14.22% +1.67

Bullish· Jan 29

MAIA Biotechnology's Phase 3 data is expected to be positive, which could lead to a significant increase in the stock price.
The company's THIO Phase 2 results were exceptional, and if Phase 3 results are similar, it could disrupt the entire cancer therapy industry and reward shareholders.
MAIA's momentum is building, with strong technical indicators, including a weekly close above the Keltner upper band and a bullish RSI reading, suggesting a potential explosive surge in the stock price.

Bearish· Jun 4

$MAIA's price drop from positive news may discourage long-term investing, but it also presents a buying opportunity.
The stock's recent price decline is a classic example of the "buy the anticipation, sell the news" phenomenon, where anticipation of positive news leads to overvaluation and subsequent sell-off.
$MAIA's significant price drop may be attributed to the market's perception that the company needs substantial funding to move forward, leading to a negative reaction from investors.

Generated by AI

Topics

Of the messages about MAIA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	85.71%	82.35%	58.25%
Technical Analysis	0%	14.29%	17.65%	23.77%
Analysts	0%	0%	0%	2.06%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.1%
Macro	0%	0%	0%	15.82%

Announcements· Dec 1

MAIA Biotechnology's CEO and board members purchased 182,445 shares in late November 2025, signaling strong confidence in their cancer drug development program.
CEO Vlad Vitoc bought 94,300 shares at an average price of $1.08, while directors Cristian Luput and Stan V. Smith purchased 88,145 shares at an average price of $1.06.
The purchases were made under the company's open market purchase plan, with the CEO and directors loading shares at an average price of $1.06-$1.08.

Technical Analysis· Jul 23

$MAIA has been consolidating in the mid-3s after reaching a high of $5.99 in early June, and is expected to break out to $5+ in coming sessions.
The stock's chart is showing strong support at $3.4-$3.55, with a break above $3.80 potentially leading to a climb back over $4 and a test of premarket highs.
$MAIA's daily and weekly charts are setting up for the next wave up, with key resistance areas at $4.00, $4.12, and $4.32.

Generated by AI

Community

Of the messages about MAIA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	92%	32.45%	31.14%
Newcomers	0%	8%	67.55%	68.86%

Regulars· Feb 4

MAIA Biotechnology has announced positive efficacy updates for its Phase 2 THIO-101 trial in advanced non-small cell lung cancer, with median overall survival reaching 16.9 months.
The trial's data strengthens MAIA's regulatory strategy, with the company potentially positioning itself for accelerated FDA approval depending on the final results.
MAIA's stock price has surged following the announcement, with some analysts predicting a potential run-up to $2.5 or even $3, driven by strong volume and the company's growth projections.

Newcomers· Jan 20

New users are focusing on the significant price increase of MAIA, with one user mentioning an uptick of 15% and another expressing interest in the stock reaching 100%+.
The newcomers are excited about MAIA's advancing cancer treatment program, specifically the ateganosine program, and the potential for early approval.
One user is highlighting the stock's recent update, which includes the potential for Phase 3 interim data and the company's plan to target the $50B+ non-small cell lung cancer (NSCLC) market.

Generated by AI

Maia Biotechnology

Social

Jun 4

Bullish· Jan 29

Bearish· Jun 4

Announcements· Dec 1

Technical Analysis· Jul 23

Regulars· Feb 4

Newcomers· Jan 20

MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

Maia Biotechnology CEO Vlad Vitoc buys $100,010 in company stock

Maia Biotechnology director buys $49,516 in company shares

MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026

Maia Biotechnology director Guerrero buys $2,386 in common stock

Also Discussed

Maia Biotechnology Inc.

Company Information

Location

MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

Maia Biotechnology CEO Vlad Vitoc buys $100,010 in company stock

Maia Biotechnology director buys $49,516 in company shares

MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026

Maia Biotechnology director Guerrero buys $2,386 in common stock

Also Discussed

Social

Jun 4

Bullish· Jan 29

Bearish· Jun 4

Announcements· Dec 1

Technical Analysis· Jul 23

Regulars· Feb 4

Newcomers· Jan 20